Welcome to our dedicated page for Keros Therapeutics SEC filings (Ticker: KROS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Keros Therapeutics, Inc. filings document a clinical-stage biopharmaceutical issuer developing therapeutics that modulate transforming growth factor-beta family signaling. Its 8-K reports cover financial results, Regulation FD corporate presentations, clinical-program announcements, collaboration disclosures, and board composition changes, while exchange registration disclosures identify Nasdaq-listed common stock and preferred share purchase rights.
The company’s proxy materials describe stockholder voting matters, board and committee governance, director compensation, and executive compensation. They also disclose portfolio strategy, including prioritization of rinvatercept, discontinued internal development activities for cibotercept, and related governance oversight of the company’s research and development focus.
Keros Therapeutics, Inc. disclosed that Chief Financial Officer Keith Regnante resigned, effective August 3, 2026, to pursue other opportunities. The Board appointed Corporate Controller and Vice President, Finance, Annita Tanini, age 55, as interim principal financial officer and principal accounting officer effective August 4, 2026, while a search for a new CFO is underway.
Under a new executive employment agreement, Ms. Tanini will receive an annual base salary of $302,300 and be eligible for an annual cash bonus targeted at 30% of base salary. If terminated without cause or she resigns for good reason, she may receive six months of base salary and up to six months of COBRA premium payments, subject to a release. Mr. Regnante will receive accrued salary and standard benefits under his existing employment agreement and is not entitled to additional severance beyond amounts required by law.
Keros Therapeutics director Jean Jacques Bienaime purchased 1,000 shares of Common Stock on July 15, 2026 at a weighted-average price of $10.61 per share, with individual trades between $10.46 and $10.80. The purchase was made under a Rule 10b5-1 trading plan adopted on December 5, 2025, increasing his direct holdings to 18,592 shares.
BlackRock Portfolio Management LLC reports beneficial ownership of common stock of Keros Therapeutics, Inc. on a Schedule 13G. The firm reports beneficial ownership of 1,122,874 shares of Keros common stock, representing 5.7% of the outstanding class.
BlackRock Portfolio Management LLC, organized in Delaware and based at 50 Hudson Yards, New York, reports sole voting power over 991,089 shares and sole dispositive power over 1,122,874 shares, with no shared voting or dispositive power. Various underlying persons may receive dividends or sale proceeds from these shares, but no single person is reported to hold more than five percent of Keros’ outstanding common stock.
Keros Therapeutics director Anne Prener received new equity awards. On July 1, 2026, she was granted 13,786 shares of Common Stock as restricted stock units (RSUs), with no cash paid per share. These RSUs vest over three years in twelve equal quarterly installments starting August 15, 2026, if she remains in continuous service.
On the same date, she was also granted a stock option for 14,870 shares of Common Stock at an exercise price of $10.88 per share, expiring on June 30, 2036. This option vests in equal quarterly installments over three years beginning October 1, 2026, also conditioned on continued service. The filing shows no open-market buying or selling; these are compensation-related grants.
Keros Therapeutics, Inc. filed an insider ownership report on Form 3 for Anne Prener
Keros Therapeutics has appointed Anne Prener, M.D., Ph.D., to its Board of Directors, effective July 1, 2026, as a Class III director with a term running through the 2029 annual stockholder meeting. She has no related-party ties to the company and joins as an independent non-employee director.
Dr. Prener will receive an initial stock option award with a grant date fair value of $150,000, capped at 0.075% of common shares outstanding, vesting quarterly over three years, plus an initial RSU award with the same value and cap vesting in 12 quarterly installments. Both awards fully vest upon a Change in Control.
On an ongoing basis, she will be eligible for annual option and RSU awards of $75,000 each, each capped at 0.0375% of shares outstanding, and will receive a $41,500 annual cash retainer. Keros also highlighted her extensive prior leadership roles at multiple biopharmaceutical companies and academic and advisory positions.
Keros Therapeutics director Jean Jacques Bienaime purchased 1,000 shares of common stock in an open‑market transaction at a weighted average price of $10.19 per share. After this buy, he directly holds 17,592 common shares. The purchase was made under a Rule 10b5-1 trading plan adopted on December 5, 2025, indicating it was pre‑scheduled rather than a discretionary trade.
Keros Therapeutics director Charles W. Newton reported an open-market sale of 550 shares of common stock at a weighted average price of $10.04 per share. The transaction occurred on June 11, 2026 and was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 12, 2026. After this sale, Newton directly holds 12,665 shares of Keros Therapeutics common stock.
Keros Therapeutics director Nima Farzan sold shares in a planned trade. On June 4, 2026, he sold 2,625 shares of Keros Therapeutics common stock in an open-market transaction at a weighted average price of $10.73 per share.
The sale was executed under a Rule 10b5-1 trading plan adopted on December 5, 2025, indicating it was pre-arranged. After these transactions, Farzan directly owns 9,767 shares of Keros Therapeutics common stock.